Cantor Fitzgerald Reiterates Overweight on Capricor Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Capricor Therapeutics, maintaining a price target of $8.
September 20, 2024 | 3:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Capricor Therapeutics, maintaining a price target of $8, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100